SUPERNUS PHARMACEUTICALS, INC. Deferred Costs, Noncurrent
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Deferred Costs, Noncurrent of $11.89 million as of 2017-06-30, per its 10-Q filed 2017-08-03.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2017-08-03
- 2017-06-30: Deferred Costs, Noncurrent $11.89M.
- 2017-03-31: Deferred Costs, Noncurrent $11.33M.
- 2016-12-31: Deferred Costs, Noncurrent $19.86M.
- 2016-09-30: Deferred Costs, Noncurrent $17.44M.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2017-06-30 | $11.89M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $11.33M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $19.86M 10-Q · filed 2017-08-03 |
| 2016-09-30 | $17.44M 10-Q · filed 2017-01-20 |
| 2016-06-30 | $16.39M 10-Q/A · filed 2017-01-23 |
| 2016-03-31 | $11.44M 10-Q/A · filed 2017-01-20 |
| 2015-12-31 | $22.50M 10-K · filed 2017-03-16 |
| 2015-06-30 | $11.49M 10-Q/A · filed 2017-01-23 |
| 2015-03-31 | $7.67M 10-Q/A · filed 2017-01-20 |
| 2014-12-31 | $5.21M 10-K/A · filed 2017-01-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |